Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Staphylococcus aureus | Quinolone resistance protein norA | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Leishmania braziliensis | hypothetical protein, conserved | Get druggable targets OG5_134723 | All targets in OG5_134723 |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trichomonas vaginalis | glycogen phosphorylase, putative | 0.0836 | 0.2577 | 1 |
Trichomonas vaginalis | DNA topoisomerase II, putative | 0.0629 | 0.1747 | 0.6778 |
Echinococcus multilocularis | Glycosyl transferase, family 35 | 0.0836 | 0.2577 | 1 |
Leishmania major | DNA topoisomerase ii | 0.0436 | 0.0977 | 0.1791 |
Schistosoma mansoni | glycogen phosphorylase | 0.0836 | 0.2577 | 1 |
Trypanosoma cruzi | mitochondrial DNA topoisomerase II, putative | 0.1555 | 0.5455 | 1 |
Plasmodium vivax | DNA topoisomerase II, putative | 0.0629 | 0.1747 | 0.1747 |
Onchocerca volvulus | Glycogen phosphorylase homolog | 0.0836 | 0.2577 | 1 |
Entamoeba histolytica | glycogen phosphorylase, putative | 0.0362 | 0.0677 | 0.2628 |
Onchocerca volvulus | DNA topoisomerase 2 homolog | 0.0629 | 0.1747 | 0.6778 |
Loa Loa (eye worm) | hypothetical protein | 0.0436 | 0.0977 | 0.379 |
Giardia lamblia | Glycogen phosphorylase | 0.0836 | 0.2577 | 1 |
Echinococcus granulosus | glycogen phosphorylase | 0.0836 | 0.2577 | 1 |
Chlamydia trachomatis | DNA gyrase subunit B | 0.1764 | 0.6292 | 0.6292 |
Echinococcus granulosus | Glycosyl transferase family 35 | 0.0836 | 0.2577 | 1 |
Echinococcus granulosus | glycogen phosphorylase | 0.0836 | 0.2577 | 1 |
Trypanosoma cruzi | DNA topoisomerase II, putative | 0.0436 | 0.0977 | 0.1791 |
Brugia malayi | DNA gyrase/topoisomerase IV, A subunit family protein | 0.0629 | 0.1747 | 0.6778 |
Trypanosoma brucei | DNA topoisomerase ii | 0.1555 | 0.5455 | 1 |
Entamoeba histolytica | glycogenphosphorylase, putative | 0.0362 | 0.0677 | 0.2628 |
Loa Loa (eye worm) | TOPoisomerase family member | 0.0629 | 0.1747 | 0.6778 |
Trypanosoma brucei | DNA topoisomerase II alpha, putative | 0.0436 | 0.0977 | 0.1791 |
Toxoplasma gondii | ATPase/histidine kinase/DNA gyrase B/HSP90 domain-containing protein | 0.1555 | 0.5455 | 1 |
Mycobacterium ulcerans | glycogen phosphorylase GlgP | 0.0362 | 0.0677 | 0.0677 |
Mycobacterium tuberculosis | DNA gyrase (subunit B) GyrB (DNA topoisomerase (ATP-hydrolysing)) (DNA topoisomerase II) (type II DNA topoisomerase) | 0.269 | 1 | 1 |
Wolbachia endosymbiont of Brugia malayi | DNA gyrase, topoisomerase II, B subunit, GyrB | 0.269 | 1 | 1 |
Mycobacterium ulcerans | DNA gyrase subunit B | 0.269 | 1 | 1 |
Trypanosoma cruzi | DNA topoisomerase II, putative | 0.0436 | 0.0977 | 0.1791 |
Mycobacterium leprae | Probable DNA gyrase (subunit B) GyrB (DNA topoisomerase (ATP-hydrolysing)) (DNA topoisomerase II) (Type II DNA topoisomerase) | 0.0926 | 0.2938 | 1 |
Trypanosoma cruzi | mitochondrial DNA topoisomerase II, putative | 0.1555 | 0.5455 | 1 |
Entamoeba histolytica | glycogen phosphorylase, putative | 0.0836 | 0.2577 | 1 |
Entamoeba histolytica | glycogen phosphorylase, putative | 0.0836 | 0.2577 | 1 |
Entamoeba histolytica | glycogen phosphorylase, putative | 0.0362 | 0.0677 | 0.2628 |
Brugia malayi | carbohydrate phosphorylase | 0.0836 | 0.2577 | 1 |
Entamoeba histolytica | DNA topoisomerase II, putative | 0.0629 | 0.1747 | 0.6778 |
Plasmodium falciparum | DNA topoisomerase 2 | 0.0629 | 0.1747 | 0.1747 |
Treponema pallidum | DNA gyrase, subunit B (gyrB) | 0.269 | 1 | 1 |
Brugia malayi | Probable DNA topoisomerase II | 0.0629 | 0.1747 | 0.6778 |
Leishmania major | mitochondrial DNA topoisomerase II | 0.1555 | 0.5455 | 1 |
Trypanosoma brucei | DNA topoisomerase II beta, putative | 0.0436 | 0.0977 | 0.1791 |
Echinococcus multilocularis | glycogen phosphorylase | 0.0836 | 0.2577 | 1 |
Giardia lamblia | DNA topoisomerase II | 0.0544 | 0.1409 | 0.5467 |
Trichomonas vaginalis | glycogen phosphorylase, putative | 0.0836 | 0.2577 | 1 |
Onchocerca volvulus | Putative DNA topoisomerase 2, mitochondrial | 0.0629 | 0.1747 | 0.6778 |
Schistosoma mansoni | glycogen phosphorylase | 0.0362 | 0.0677 | 0.2628 |
Echinococcus granulosus | DNA topoisomerase 2 alpha | 0.0629 | 0.1747 | 0.6778 |
Onchocerca volvulus | DNA topoisomerase 2 homolog | 0.0629 | 0.1747 | 0.6778 |
Plasmodium falciparum | DNA gyrase subunit B | 0.269 | 1 | 1 |
Brugia malayi | DNA topoisomerase II, alpha isozyme | 0.0629 | 0.1747 | 0.6778 |
Plasmodium vivax | DNA gyrase subunit B, putative | 0.269 | 1 | 1 |
Echinococcus multilocularis | glycogen phosphorylase | 0.0836 | 0.2577 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0436 | 0.0977 | 0.379 |
Echinococcus multilocularis | DNA topoisomerase 2 alpha | 0.0629 | 0.1747 | 0.6778 |
Toxoplasma gondii | DNA topoisomerase 2, putative | 0.0629 | 0.1747 | 0.3202 |
Schistosoma mansoni | DNA topoisomerase II | 0.0629 | 0.1747 | 0.6778 |
Schistosoma mansoni | glycogen phosphorylase | 0.0836 | 0.2577 | 1 |
Chlamydia trachomatis | glycogen phosphorylase | 0.0836 | 0.2577 | 0.2577 |
Loa Loa (eye worm) | glycogen phosphorylase | 0.0836 | 0.2577 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 9.7 uM | Inhibition of NorA in Staphylococcus aureus 1199B harboring grlA A116E mutant assessed as inhibition of ethidium bromide efflux measured for 5 mins by fluorometric analysis | ChEMBL. | 23710549 |
Inhibition (binding) | = 91 % | Inhibition of NorA in Staphylococcus aureus 1199B harboring grlA A116E mutant assessed as inhibition of ethidium bromide efflux at 50 uM measured for 5 mins by fluorometric analysis relative to control | ChEMBL. | 23710549 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.